Skip to main content

Table 1 Demographic and disease characteristics for PsA patients

From: Differences in oxylipin profile in psoriasis versus psoriatic arthritis

Variable Psoriatic arthritis (N=19)
Age (years) (mean, SD) 60.5 (± 11.4)
Sex F:M 7:12 (63.1% male)
BMI (kg/m2) (mean, SD) 31.9 (± 5.6)
PsO (%) 63.1%
PASI 3 (± 5.1)
BSA (%) 4.7 (± 11)
TJC (mean, SD) 9.3 (± 10.4)
SJC (mean, SD) 3.7 (4.2)
VAS Activity (mean, SD) 59.1 (± 28.7)
VAS Pain (mean, SD) 43.5 (± 32.2)
Enthesitis (%) 63.1%
Enthesitis (mean, SD) 2.2 (± 3)
cDAPSA 23.4 (11.4)
NSAIDs (%) 16.7%
DMARDs (%) 26.3%
TNF alpha inhibitors (%) 47.3%
Corticosteroids (%) 0
Topical corticosteroids (%) 26.3%
  1. BMI body mass index, PASI Psoriasis Area and Severity Index, BSA body surface area, TJC tender joint count, SJC swollen joint count, VAS visual analog scale, HAQ Health Assessment Questionnaire, NSAID non-steroid anti-inflammatory drugs, TNF tumor necrosis factor, DMARDs disease-modifying anti-rheumatic drugs.